Preexisting diabetes, metformin use and long-term survival in patients with prostate cancer.

Donata Linkeviciute-UlinskieneAusvydas PatasiusMarius KinciusLina ZabulieneGiedre Smailyte

Published in: Scandinavian journal of urology (2020)

There was no difference in long-term prostate cancer-specific survival in patients with or without T2DM. Overall survival was lower in T2DM patients not treated with metformin.

Keyphrases

prostate cancer
radical prostatectomy
newly diagnosed
end stage renal disease
ejection fraction
glycemic control
type diabetes
cardiovascular disease
prognostic factors
free survival
metabolic syndrome
insulin resistance